Crescent Biopharma, Inc. (CBIO) stock
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30
$14.37−0.39 (-2.61%)
Close on Nov 12, 2026Market cap $533.76MP/E –Yield –
Crescent Biopharma statistics
74 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Q3 FY2026, expected soon
- Last ex-dividend date
- Jan 13, 2023
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 12, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 1.95
- 2.29
Enterprise valuationIndustry
- EV / Sales
- 16.29
- 2.60
Share statisticsIndustry
- Shares Change (QoQ)
- 37.6%
- 0.51%
- Float
- 23M
- 49M
- Shares Held by Insiders
- 38.6%
- 12.1%
- Shares Held by Institutions
- 79.7%
- 56.4%
Short sellingIndustry
- Short Interest
- 4M
- –
- Short Interest Change
- -5.85%
- -0.76%
- Short % of Float
- 18.3%
- 9.04%
- Short % of Shares Outstanding
- 11.2%
- 6.30%
- Days to Cover
- 16.29
- 5.13
Stock price statisticsIndustry
- 52-Week High
- $27.41
- –
- 52-Week Low
- $8.72
- –
- 20-Day Moving Average
- $13.32
- –
- 50-Day Moving Average
- $14.93
- –
- 200-Day Moving Average
- $15.93
- –
- Average True Range (14)
- $1.09
- –
- Price Change (1 Week)
- 11.1%
- 1.51%
- Price Change (1 Month)
- 14.2%
- -2.35%
- Price Change (3 Months)
- -16.2%
- -21.1%
- Price Change (6 Months)
- -32.3%
- -22.6%
- Price Change (YTD)
- 21.2%
- -22.6%
- Price Change (1 Year)
- 8.45%
- -20.7%
- Price Change (3 Years)
- -89.2%
- -27.4%
- Price Change (5 Years)
- -93.3%
- -77.3%
- Price Change (10 Years)
- -97.8%
- -62.7%
- Average Volume (10 Days)
- 185,236
- –
- Average Volume (20 Days)
- 225,938
- –
- Average Volume (90 Days)
- 350,556
- –
- Relative Volume
- 0.60
- 0.79
- Relative Strength Index (14)
- 54.2
- 44.7
- Volatility (1 Year)
- 81.0%
- 80.4%
- Beta (5 Years)
- 1.63
- 1.07
MarginsIndustry
- EBITDA Margin
- -1216.6%
- -27.7%
- FCF Margin
- -549.5%
- -9.20%
Returns on capitalIndustry
- Return on Equity (ROE)
- -55.8%
- -51.2%
- Return on Assets (ROA)
- -49.9%
- -40.6%
- Return on Capital Employed (ROCE)
- -66.1%
- -38.0%
Financial positionIndustry
- Current Ratio
- 12.57
- 3.30
- Quick Ratio
- 12.32
- 2.42
GrowthIndustry
- Revenue Growth (3Y CAGR)
- 424.9%
- 2.25%
- Revenue Growth (5Y CAGR)
- 1.31%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.07
- 0.40
- Revenue Per Employee
- $340.91K
- $429.29K
- Profits Per Employee
- -$2.48M
- -$683.67K
- Employee Count
- 44
- 75
- WACC
- 13.1%
- 10.1%
Income statement (TTM)Industry
Balance sheetIndustry
- Net Cash (Debt)
- $289.36M
- $17.46M
- Net Cash Per Share
- $7.79
- $0.72
- Equity (Book Value)
- $274.28M
- $53.27M
- Book Value Per Share
- $7.38
- $1.50
- Tangible Book Value
- $274.28M
- $26.82M
- Working Capital
- $271.72M
- $79.47M
Cash flow (TTM)Industry
- Capital Expenditures
- -$353.00K
- -$944.00K
- FCF Per Share
- -$2.22
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -20.4%
- -20.8%
- FCF Yield
- -15.4%
- -9.58%
Taxes and interestIndustry
- Interest Expense
- $0
- $2.93M
- Income Tax
- $2.00M
- $74.00K
Scores and fair valueIndustry
- Altman Z-Score
- 10.62
- 0.30
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CBIO | S&P 500 | Difference | CBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.6% | -2.7% | +2.1 pts | ||
| 3 months | -12.5% | -1.7% | −10.8 pts | ||
| Year to date | +21.2% | +11.9% | +9.3 pts | ||
| 1 year | +10.1% | +12.0% | −1.9 pts | ||
| 3 years | -88.0% | +78.2% | −166.2 pts | -50.7% | +21.2% |
| 5 years | -92.6% | +73.2% | −165.9 pts | -40.7% | +11.6% |
| 10 years | -97.6% | +309.6% | −407.3 pts | -31.3% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
4M CBIO shares were sold short on Oct 30, 2026, down 5.8% from the previous report, or 18.26% of the shares available to trade. At recent volumes it would take 16.3 days to buy them back. Over the last 20 sessions, 64.7% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 4,160,829 | -5.8% | 255,474 | 16.3 |
| Oct 15, 2026 | 4,419,185 | -7.5% | 349,105 | 12.7 |
| Sep 30, 2026 | 4,777,172 | +40.2% | 697,402 | 6.8 |
| Sep 15, 2026 | 3,407,158 | +7.4% | 400,407 | 8.5 |
| Aug 31, 2026 | 3,172,374 | -1.4% | 159,313 | 19.9 |
| Aug 14, 2026 | 3,216,698 | -7.2% | 187,795 | 17.1 |
| Jul 31, 2026 | 3,465,334 | -7.4% | 388,342 | 8.9 |
| Jul 15, 2026 | 3,743,278 | +1.9% | 384,904 | 9.7 |
| Jun 30, 2026 | 3,673,343 | +9.8% | 522,826 | 7.0 |
| Jun 15, 2026 | 3,346,536 | +2.7% | 212,363 | 15.8 |
| May 29, 2026 | 3,257,490 | +12.3% | 289,116 | 11.3 |
| May 15, 2026 | 2,901,354 | +21.1% | 344,475 | 8.4 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?